title: The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.
abstract: To determine the antiviral effects of compounds against ocular adenovirus (AdV) infection, we established an animal model of AdV infection in cotton rat eyes. Cotton rat eyes were inoculated intrastromally and topically with four AdV serotypes 4, 5, 8, and 37, and treated topically with 1% HPMPC (cidofovir) eye drops twice a day. The infected corneas were extracted and homogenized, and virus titers in the cornea specimens were determined by a plaque assay. The virus titer in AdV type 5-inoculated eyes peaked on days 0 through 3 after inoculation and virus shedding was detected for 18.0+/-2.8 days. AdV 5 antigen in the infected corneas was demonstrated in the corneal epithelial cells by immunofluorescence stain. However, for AdV serotypes 4, 8, and 37, no evidence of continued virus replication in cotton rat eyes was noted. Specimens from cidofovir-treated eyes infected with AdV 5 demonstrated a statistically significant reduction in the mean virus titer (days 3-15) (P=0.028) and virus shedding duration (P=0.0014), as compared with those of the control group.
authors.affiliation: Department of Microbiology, Fukushima Medical University School of Medicine, 1, Hikarigaoka, Fukushima 960-1295, Japan. h-kane@chive.ocn.ne.jp
authors.forename: Hisatoshi
authors.initials: H
authors.lastname: Kaneko
authors.forename: Shuichi
authors.initials: S
authors.lastname: Mori
authors.forename: Osamu
authors.initials: O
authors.lastname: Suzuki
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Iida
authors.forename: Shiro
authors.initials: S
authors.lastname: Shigeta
authors.forename: Masafumi
authors.initials: M
authors.lastname: Abe
authors.forename: Shigeaki
authors.initials: S
authors.lastname: Ohno
authors.forename: Koki
authors.initials: K
authors.lastname: Aoki
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Suzutani
mesh_terms: D000257:Adenoviridae Infections / Q000188:drug therapy* / Q000821:virology; D000260:Adenoviruses, Human / Q000187:drug effects* / Q000254:growth & development; D000287:Administration, Topical; D000818:Animals; D000956:Antigens, Viral / Q000032:analysis; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077404:Cidofovir; D003236:Conjunctivitis, Viral / Q000188:drug therapy; D003315:Cornea / Q000821:virology; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D015828:Eye Infections, Viral / Q000188:drug therapy*; D005260:Female; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D016205:Sigmodontinae; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects; D017201:Virus Shedding / Q000187:drug effects
chemical_list: D000956:Antigens, Viral; D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir